Literature DB >> 25043643

Beta-lactam antibiotic dosing during continuous renal replacement therapy: how can we optimize therapy?

Jan J De Waele, Mieke Carlier.   

Abstract

Correct antibiotic treatment is of utmost importance to treat infections in critically ill patients, not only in terms of spectrum and timing but also in terms of dosing. However, this is a real challenge for the clinician because the pathophysiology (such as shock, augmented renal clearance, and multiple organ dysfunction) has a major impact on the pharmacokinetics of hydrophilic antibiotics. The presence of extra-corporal circuits, such as continuous renal replacement therapy, may further complicate this difficult exercise. Standard dosing may result in inadequate concentrations, but unadjusted dosing regimens may lead to toxicity. Recent studies confirm the variability in concentrations, and the wide variation in dialysis techniques used certainly contributes to these findings. Well-designed clinical studies are needed to provide the data from which robust dosing guidance can be developed. In the meantime, non-adjusted dosing in the first 1 to 2 days of antibiotic therapy during continuous renal replacement therapy followed by dose reduction later on seems to be a prudent approach.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25043643      PMCID: PMC4075247          DOI: 10.1186/cc13945

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


  6 in total

Review 1.  Quality of pharmacokinetic studies in critically ill patients receiving continuous renal replacement therapy.

Authors:  S Vaara; V Pettila; K-M Kaukonen
Journal:  Acta Anaesthesiol Scand       Date:  2011-10-19       Impact factor: 2.105

2.  Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT.

Authors:  Seth R Bauer; Charbel Salem; Michael J Connor; Joseph Groszek; Maria E Taylor; Peilin Wei; Ashita J Tolwani; William H Fissell
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 8.237

3.  Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.

Authors:  Darren M Roberts; Jason A Roberts; Michael S Roberts; Xin Liu; Priya Nair; Louise Cole; Jeffrey Lipman; Rinaldo Bellomo
Journal:  Crit Care Med       Date:  2012-05       Impact factor: 7.598

4.  Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.

Authors:  Lucie Seyler; Frédéric Cotton; Fabio Silvio Taccone; Daniel De Backer; Pascale Macours; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Crit Care       Date:  2011-06-06       Impact factor: 9.097

5.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

Authors:  Jason A Roberts; Sanjoy K Paul; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079

6.  β-lactam antibiotic concentrations during continuous renal replacement therapy.

Authors:  Marjorie Beumier; Giuseppe Stefano Casu; Maya Hites; Lucie Seyler; Frederic Cotton; Jean-Louis Vincent; Frédérique Jacobs; Fabio Silvio Taccone
Journal:  Crit Care       Date:  2014-05-22       Impact factor: 9.097

  6 in total
  3 in total

1.  Beta-lactam dosing during continuous renal replacement therapy: a survey of practices in french intensive care units.

Authors:  Elodie Matusik; Justine Lemtiri; Guillaume Wabont; Fabien Lambiotte
Journal:  BMC Nephrol       Date:  2022-01-29       Impact factor: 2.388

Review 2.  Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients.

Authors:  Rui Pedro Veiga; José-Artur Paiva
Journal:  Crit Care       Date:  2018-09-24       Impact factor: 9.097

3.  A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration.

Authors:  Fekade B Sime; Melissa Lassig-Smith; Therese Starr; Janine Stuart; Saurabh Pandey; Suzanne L Parker; Steven C Wallis; Jeffrey Lipman; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.